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Role of information in preparing men for
transrectal ultrasound guided prostate biopsy: a
qualitative study embedded in the ProtecT trial
Julia Wade1*, Derek J Rosario2, Joanne Howson3, Kerry N L Avery1, C Elizabeth Salter1, M Louise Goodwin2,
Jane M Blazeby1, J Athene Lane1, Chris Metcalfe1, David E Neal4, Freddie C Hamdy5 and Jenny L Donovan1
Abstract
Background: The histological diagnosis of prostate cancer requires a prostate needle biopsy. Little is known about
the relationship between information provided to prepare men for transrectal ultrasound guided biopsy (TRUS-Bx)
and how men experience biopsy. The objectives were a) to understand men’s experiences of biopsy as compared
to their expectations; and b) to propose current evidence-based information for men undergoing TRUS-Bx.
Methods: Between February 2006 and May 2008, 1,147 men undergoing a standardised 10-core transrectal ultrasound
guided biopsy protocol under antibiotic cover following a PSA 3.0-19.9 ng/ml in the Prostate Testing for Cancer and
Treatment (ProtecT) trial, completed questionnaires about biopsy symptoms. In this embedded qualitative study,
in-depth interviews were undertaken with 85 men (mean age 63.6 yrs, mean PSA 4.5 ng/ml) to explore men’s
experiences of prostate biopsy and how the experience might be improved. Interview data were analysed
thematically using qualitative research methods. Findings from the qualitative study were used to guide selection of
key findings from the questionnaire study in developing a patient information leaflet preparing men for biopsy.
Results: Although most men tolerated TRUS-Bx, a quarter reported problematic side-effects and anxiety. Side
effects were perceived as problematic and anxiety arose most commonly when experiences deviated from information
provided. Men who were unprepared for elements of TRUS-Bx procedure or its sequelae responded by contacting
health professionals for reassurance and voiced frustration that pre-biopsy information had understated the possible
severity or duration of pain/discomfort and bleeding. Findings from questionnaire and interview data were combined
to propose a comprehensive, evidence-based patient information leaflet for TRUS-Bx.
Conclusions: Men reported anxiety associated with TRUS-Bx or its side-effects most commonly if they felt inadequately
prepared for the procedure. Data from this qualitative study and the previous questionnaire study have been used to
propose an updated, comprehensive evidence-based set of information for men undergoing TRUS-Bx.
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Background
Prostate cancer (PCa) is the second most common cause
of cancer death in European men [1] with an incidence rate
of 214 cases per 1000 [2]. Biopsy is required for histological
diagnosis of PCa. Moreover, as active surveillance (AS)
becomes increasingly accepted as an alternative to radical
treatment for localised PCa [3], scheduled re-biopsy is also
used as a monitoring tool. Transrectal ultrasound guided
biopsy (TRUS-Bx) is therefore one of the most commonly
performed urological procedures with over one million pro-
cedures performed each year in Europe and the United
States (US) [4]. A recent systematic review of complications
arising from TRUS-Bx found that, although symptoms of
minor bleeding or urinary complications are common, they
do not usually require intervention; infective complications,
though uncommon, can be serious and require rapid inter-
vention [4].
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Population screening for PCa using prostate specific
antigen (PSA) testing is currently not recommended,
due to ongoing controversies regarding the net balance
of benefits against harms, including potential harms of
prostate biopsy [5-7]. Instead, European Association of
Urology (EAU) guidelines on PCa recommend that op-
portunistic PSA screening should be offered to the well-
informed man [8]. Men in the United Kingdom (UK) are
provided with information about the advantages and
disadvantages of PSA testing, prostate biopsy and pros-
tate cancer treatments to facilitate shared or informed
decision-making [9]. This process of shared and in-
formed decision-making requires that patients be given
accurate and comprehensive information about prostate
biopsy and its sequelae [10].
The Prostate Biopsy Effects (ProBE) study [11], is the
largest prospective cohort study to date of morbidity arising
from TRUS-Bx, based on men receiving a standardized
biopsy protocol as part of the ProtecT (Prostate testing for
cancer and Treatment) randomised controlled trial (RCT).
The ProBE study investigated men’s experiences of physical
sequelae and impact on health-related quality of life
(HRQL), including healthcare use [11] and anxiety [12],
using data from self-report questionnaires. The ProBE
study [11] found that the prevalence of post-biopsy
symptoms was higher as compared to previous reports
[13,14]. In addition, although symptoms were rated as a
‘major’ or ‘moderate’ problem by a minority only (pain =
7.3%, fever = 5.5%, haematuria = 6.2%, heamatochezia =
2.5%, heamoejaculate = 26.6%), more than one quarter
(27.1%) reported one or more symptoms as problematic
(i.e. a ‘moderate’ or ‘major’ problem) during the 35 days
post-biopsy [11]. Further analysis found that men experi-
encing symptoms as a ‘major’ or ‘moderate’ problem were
more likely to report increased anxiety at seven days post
biopsy prior to the biopsy outcome being known and re-
gardless of the ultimate biopsy result [12]. What remained
unclear was why around one quarter of men experienced
symptoms as problematic and how associated anxiety arose.
The present study addresses these issues. It reports a
qualitative in-depth interview study embedded within the
ProBE/ProtecT studies (a) to understand men’s experiences
of biopsy as compared to expectations before biopsy; and
(b) to propose current evidence-based information for men
undergoing TRUS-Bx with a view to minimising anxiety
associated with problematic symptoms [12].
Methods
ProBE/ProtecT study designs
The ProBE study investigated impacts of TRUS-Bx in
a population invited for PSA testing (for details see
Rosario et al. [11]). Briefly, from February 2006 to May
2008, 1,147 (65%) of 1,753 ProtecT study participants aged
50–69 years, with a raised PSA result (3.0 -19.9 ng/ml)
were invited for digital rectal examination (DRE), repeat
PSA test and standardized 10-core TRUS-Bx under anti-
biotic cover [11]. Men returned purpose designed ques-
tionnaires assessing the physical harms of biopsy at seven
and 35 days post biopsy and the Hospital Anxiety and
Depression Scale [15] assessing the psychological status at
the time of initial PSA test, at time of biopsy and at seven
days (before biopsy result was known) and 35 days post
biopsy (after biopsy result was known). Further details
of data collection and analysis in the questionnaire study
are reported elsewhere [11,12]. A pre-study questionnaire
completed by each ProBE study centre showed that seven
out of eight study centres routinely administered local an-
aesthetic prior to biopsy. All men invited to join the ProBE
study received patient information leaflets (PILs) on the
ProBE and ProtecT studies, as well as the relevant local
hospital TRUS-Bx PILs and explanations from staff carry-
ing out the procedure (see Additional file 1 for a sample
PIL used by one study centre). Ethical approval was ob-
tained from Trent Multicentre Research Ethics Commit-
tee, UK. All participants gave informed consent.
Participants in the qualitative study
Three groups of participants were recruited to the qua-
litative investigation of the TRUS-Bx experience. Using
maximum variation sampling to include men with a wide
range of characteristics and biopsy experiences, 45 ProBE
study participants with a range of ages, socio-economic
backgrounds and various biopsy outcomes were invited
for interview. Experience of post-biopsy infection was not
captured in this sample; therefore five additional men with
confirmed infection were sampled from ProBE study par-
ticipants. Within the ProtecT study, a further 53 men pur-
posively sampled to achieve maximum variation sampling
were invited for interviews investigating their experiences
of participating in the study [16] and including questions
about their experience of biopsy.
Interviews
In-depth qualitative interviews were conducted after bi-
opsy result was known in the ProBE study by KNLA
(Table 1, A1-A33) and JW (Table 1, A34i-A38i) a median
of 10 and 18 weeks following biopsy, and within the Pro-
tecT study, by JW, CES and JLD (Table 1, B39-B85) a
median of 41 weeks after biopsy. Interviews were by
telephone or face-to-face in each man’s preferred loca-
tion. Interviews were semi-structured using a topic guide
(see Issues covered by Topic Guide) to elicit expecta-
tions and actual experiences of TRUS-Bx and its seque-
lae and reflect on how negative impacts might be
mitigated, whilst simultaneously allowing men to raise
individual issues.
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Table 1 Characteristics of in-depth interview study participants, N = 85
ProBE/ProtecT participants N = 38 ProtecT participants N = 47 All participants
No infection
(N = 33, A1-A33)
Infection (i)
(N = 5, A34i-A38i)
(N = 47, B39—B85) (N = 85)
Age at time of first biopsy: mean (SD) 64.3 (4.9) 60.8 (4.9) 63.5 (4.5) 63.6 (4.7)
Employment status N (%)
Full time 14 5 24 43
Not working 18 0 20 38
Part time 0 0 0 0
Not specified/missing 1 0 3 4
Ethnicity, N (%)
White 33 5 46 84
Other 0 0 1 1
Centre, N (%)
1 3 0 0 3
2 1 0 9 10
3 16 3 30 49
4 2 0 8 10
5 4 0 0 4
6 3 1 0 4
7 2 1 0 3
8 2 0 0 2
Initial PSA result ng/ml, median (Interquartile range) 6.0 (3.7 to 13.0) 4 (3.4 to 4.7) 4.3 (3.5 to 6.7) 4.5 (3.5 to 7.2)
Biopsy result (Final biopsy)
Benign 12 1 0 13
Localized cancer 12 4 47 63
Advanced cancer 9 0 0 9
Number of biopsies at time of interview
1 33 5 35 73
2 0 0 10 10
3 0 0 2 2
Interview type
Telephone 18 5 0 23
Face to face 15 0 47 62
Timing of interview N weeks post-biopsy
Median (range) mean
10 (3–138) 33 18 (10–72) 35 41 (9–75)* 41 40 (3–138) 39
Treatment of infection
Hospital admission n/a 3 n/a 3
Family physician n/a 2 1** 3
Cancer treatment
Radical prostatectomy − - 17 17
Radical radiotherapy - - 15 15
Active monitoring - - 15 15
Other - - 0 0
*calculated from date of most recent biopsy if more than one biopsy took place**1 man was prescribed antibiotics having consulted his family physician about
post-biopsy bleeding; there was no evidence that this man actually experienced an infection.
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Issues covered by interview topic guide
Expectations of biopsy – understanding of purpose,
procedures, comments on information received
Experience of biopsy – physical/psychological – what
could have been improved in procedures or information
Effects of biopsy – physical/psychological/sexual,
duration
Experience of infection – symptoms, decision to seek
help, treatment, impact, what could have been improved
Recommendations for change - procedures or
information
Views on repeat biopsy
*see Avery et al. 2008 [17] for full range of topics
covered in interviews with ProBE men.
Analysis
Analysis focussed on interview data relating to topics
listed in the interview topic guide. Interviews were audio-
recorded, transcribed verbatim and transcripts scrutinized
to identify recurrent themes. Interviews were analysed in
groups (e.g. according to biopsy outcome, experience of
infection, number of biopsies) and individually to identify
commonalities and contrasts between groups or individ-
uals. The interview topic guide was refined during the
interview process as themes emerged, in accordance with
constant comparison methods derived from grounded the-
ory [18,19]. Data collection and analysis were carried out
iteratively with analysis guiding further sampling for ex-
ample including men experiencing infection, until no new
findings emerged. Analysis was facilitated by use of quali-
tative computer software, NVivo [20] and led by JW, with
a subset of 33 transcripts analysed independently by JLD.
Emergent findings were discussed and synthesised to
maximise reliability of thematic coding and data interpret-
ation [18,19].
Development of proposed biopsy patient information leaflet
Findings from the questionnaire study [11] provided
current generalizable quantitative data on the physical
sequelae that may be expected in the 35 days following
biopsy. Findings from the interview study were combined
with these quantitative data to propose a revised set of
information to be given to men undergoing TRUS-Bx.
Results
Interviews were conducted with 38 of 45 men (84%,
A1-A38, Table 1) from within ProBE and with 47 of 53
men (89%, B39-B85, Table 1) from within ProtecT. Data
from interviews with 85 men with a broad range of
characteristics were analysed (Table 1). Findings revealed
that pre-biopsy information provision played a key role
in determining how men experienced biopsy: how well-
prepared they were had potentially more influence than
the severity of their symptoms in influencing how they
experienced TRUS-Bx and its sequelae.
Levels of preparedness
Most men (N = 64) reported feeling adequately prepared
for TRUS-Bx and described the experience as matching
what they expected from the PIL or pre-biopsy discussions:
‘It was exactly as explained to me in the notes,
so you have no recourse’ (B52).
‘Nothing was a shock, what actually happened,
because I was told exactly what happened. What
was going to happen did happen, there were no
nasty shocks involved’ (A5).
Several commented on the effect of previous experi-
ences of ‘close inspection’ or painful treatments. Six men
believed such experiences (endoscopies, treatment for
haemorrhoids, a hip operation, a liver biopsy and spinal
surgery) made TRUS-Bx less alarming:
‘The biopsy was child’s play compared to that
(previous endoscopy investigation)’ (B47).
‘I’ve had spinal operations and that recently, so
nothing tends to faze me’ (A3)
Two men, who had no previous experience of hospital
treatment, reported this made biopsy more challenging:
‘For someone who has really never really been in
hospital, it becomes a big thing’ (A4)
A substantial minority (21/85, 25%) reported feeling
unprepared in a number of ways relating to experience of
blood loss, pain, infective symptoms, aspects of biopsy
procedure or terminology and repeat biopsy experiences.
Men highlighted the discrepancy in their experience
between what they expected and what they experienced in
terms of quantity, duration, site, colour and the intermittent
pattern of bleeding:
‘I had no idea just how much blood would come
through…and I think it would be an idea to warn
people…to use a condom…that would save a lot of
embarrassment and grief ’ (A4).
‘I didn’t expect the blood when I stood up [post
biopsy] because it was a lot happening in the back
passage so for it to come out of the penis down your
legs was a bit sort of ‘hm!’ I was told it could go on
for 48 hours, sometimes a bit longer, but it kept on
for about 2 weeks’. (B73)
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‘The other thing they didn’t tell you on that [PIL] is
that you when you’ve had the biopsy, you get blood in
your semen, not red blood, black.’(A7)
Information failed to prepare men for the range of
experiences of pain:
‘I found it incredibly painful and distressing…in an
emotional sense…biopsy with a nail gun. She (nurse)
said “some people find discomfort”, I think that
was a euphemism’ (A33)
‘I felt invaded, it took me to my limit…I’ve had this
terrible battering (B62).
Some (4/85) emphasised the experience of distress
associated with the procedure, even when pain was well
controlled:
‘I must admit it was a little more severe than I’d
anticipated, I nearly passed out…There wasn’t any
actual pain just discomfort when you’ve got a tube
rammed up your back (side)’ (A1).
These men emphasised that distress or anxiety was not
necessarily linked to severity or duration of symptoms per se
but arose where there was a disparity between expected and
actual experience (see comments highlighted in bold above).
Men experiencing infection reported both alarm at the
severity of infective symptoms and simultaneous uncertainty
about the appropriate response:
‘Then within an hour I started uncontrollable shakes
and shivering, but felt really hot and eventually I said
‘I can’t play this [board game with friends] anymore
I’m going to have to go home’. I got home and I went
straight to bed. ((Wife’s name)) read the leaflet on from
the biopsy and saw about ‘flu symptoms and stuff like
that. So on the Saturday morning she rung the
emergency doctor and the doctor said just go straight
to [emergency service]. And me being me, I was totally
out of it and in bed and she said ‘We’ve got to go to
[emergency service]’ and I said ‘Oh I’m not going to
any hospital [emergency service].” (A35i)
‘My son came from work, and I said ‘Please take me to
the hospital because I’m not feeling very well and I’m
shivering’. And I hadn’t told him about the biopsy, I
hadn’t told him anything, and he said, ‘Don’t be so
daft, get into bed like’, you know, as you would. ‘You
can’t go to hospital for the shivers, because you’re
shivering’. So, I then had to tell him, about the biopsy
and things. And, so he took me to the [out of hours’
family physician service].’ (A36i)
One also reported an inappropriate response from the
emergency doctor when he presented with post-biopsy
infection:
‘They said at the hospital when you were having the
biopsy they said ‘should you get any ‘flu-like symptoms,
don’t hesitate to go to the hospital and tell them, tell
them what you’ve had [done]’. And I go into [hospital
name] on the Sunday afternoon, the first of the
doctors, you know, looked in complete amazement at
me: ‘What are they sending me people like this for?
I’ve got enough problems to deal with.’ (A36i)
Aspects of TRUS-Bx terminology or procedure caused
confusion. Some men were not prepared for ten biopsy
cores, expecting ‘a single prostate biopsy’.
‘They took 10 biopsies, which was a lot more than I
thought they were going to do, which concerned me a
little bit. Ten biopsies, what do they need 10 biopsies
for, how big is this thing? You know it’s the size of a
golf ball, how the hell do they get 10?’ (A5)
Others reported fear of TRUS-Bx causing cancer spread,
confusion over why they should bring a friend or relative
to the appointment, and surprise that staff present were
all female:
‘I wondered about how safe the biopsy procedure is.
Whether by firing ten holes into the prostate that
doesn’t increase the risk of malignant cells escaping
from what I think you call the prostatic capsule....Since
I had my biopsy that was now about five weeks ago,
for a lot of time I’ve had a sort of discomfort in the
lower stomach area.’ (A27)
‘I didn’t even know if they were going to give me an
injection and knock me out…I had a horrible feeling
that was what was going to happen if they needed
somebody else with me to get me home.’ (A12)
‘I walked into the doctors surgery and it was a female
nurse and a female doctor and they were both good
looking girls and you know, there was two other women
in there and I’ve no idea whoever they were but they
was looking quite busy and I was lying on this bed with
my trousers and pants down round my ankles and I’m
thinking it’s not the right place for this’. (B67)
Men undergoing repeat diagnostic TRUS-Bx were not
prepared for these seeming more invasive and painful:
‘I hardly felt any discomfort with the first one, it was
over in no time at all, just slightly, slightly unpleasant.
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The second one took a lot longer, had a lot of bleeding,
took longer, far more invasive and I felt, I felt poorly
after…sicky discomfort in my lower region and it felt
far more invasive than the first one’. (B50)
‘But the second one [biopsy procedure] made me jump
because, I don’t know whether with the first one they
kind of took the edge of it and the second time it went
right through the middle and it certainly made me go
“ooh”’. (B49)
Impact of unanticipated TRUS-Bx experiences
Failure to prepare men adequately for TRUS-Bx or its
sequelae had a number of consequences. The most com-
mon was anxiety (see also Wade et al. [12] who found
that men who experienced symptoms as problematic
had raised anxiety). This in turn prompted some men to
consult health professionals for advice (see also Rosario
et al. [11] who reported 119/1147 or 10.4% men con-
tacted health professionals for advice in this way):
‘The danger is if you say to people that [it] could bleed
up to a fortnight, that’s what your little mind tells you.
But a week after that, I started bleeding again, so I
had to phone my doctor’. (B62)
‘But when we got to week four or five and I was still
noticing that [blood in urine] then I made the phone
call to ask is this as it should be. For some men to find
that they were experiencing blood stains….for a period
afterwards, would worry some people more than
perhaps me’. (B52)
In most cases (i.e. where there were no infective symp-
toms) men were simply reassured that symptoms were
normal. Men reported frustration at not being adequately
prepared, as it would have avoided both unnecessary anx-
iety and consultations:
‘It wouldn’t be bad if they were advised that this is
something that they should anticipate’. (B52)
‘I wish they would have told me that, at the start
you know’ (A28)
These views contrasted with those whose experiences
conformed to information provided.
‘I was well advised as to what would happen on the
blood in the urine and blood in the semen and that
sort of thing. And it wasn’t then unexpected. I was
quite well prepared. And, true to form, they said,
you know, it’s sort of three to four weeks or whatever
it’ll dissipate. Which it did. And so I was well
advised, and I’ve no complaints whatsoever on that
score.’ (B65)
The biopsy experience influenced subsequent PCa treat-
ment decision-making or management for some. Four of
the five men experiencing post-biopsy infection reported
reluctance to undergo repeat TRUS-Bx:
‘I wouldn’t hesitate because of the procedure. What I
would hesitate would be the possibility of infection and
the treatment you get when you get an infection’. (A36i).
‘But I did say that I would not have that [biopsy]
done again, because of, because I caught the infection.
The actual [biopsy] itself um, as I said was quite
uncomfortable, but I mean I could manage that. But
it was the, the infection afterwards, that, that done it
for me really.’ (A37i)
One man refused radical prostatectomy (RP) treatment
because his experience of longer bleeding than described
in the information convinced him he would experience
more severe side-effects than outlined in prostatectomy
information:
‘But the worrying aspect that I found, was that I had
read literature which led me to expect 24 to 48 hours
[bleeding]. Several days and it was running into the
weekend after I had had the biopsy, I was still passing
up quite a lot of blood, so I rang up the emergency
doctor cover at the weekend to get some advice and
the advice from the doctor was he would give me
some more antibiotics…then I thought, ah now, if in
fact my post-surgery experiences reflect my post
biopsy experiences then the expectation of a relatively
quick recovery or recovery at all might be quite prolonged’.
How information provision might be improved
Men, who felt prepared, reported that clinical staff had
not only provided the PIL but also talked through the
procedure and gave opportunities to ask questions and
clarify misunderstandings:
‘The staff in the hospital I had the biopsy, they
explained all this to me. So I wasn’t scared when
I seen this blood. It’s what I expected.’ (B70).
‘Everything to me- for me - was explained explicitly before
and I was told what to expect, so by the time I went in for
the biopsy, I knew exactly what was going to happen…so
everything worked like clockwork you know.’ (B51)
Men suggested that pre-biopsy information they received
had been too conservative regarding the range of experience
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they should have expected. Recommendations for im-
provements to patient information about TRUS-Bx are
summarised in Table 2. Proposed content for a more com-
prehensive TRUS-Bx PIL, combining current quantitative
data from the ProBE questionnaire study [11] and insights
from the present study, is presented in Additional file 2.
Discussion
This qualitative study revealed that anxiety associated with
TRUS-Bx arose most commonly when experiences or
symptoms deviated or were more severe than described in
pre-biopsy information. Men responded to anxiety by con-
tacting health professionals for reassurance and most
received reassurance rather than active treatment. Men
suggested that improvements to pre-biopsy information
provision were needed. Given that the prevalence of any
haemorrhagic or infective symptoms in the 35 days follow-
ing TRUS-Bx is known to be 94.0% and in 27.1% symp-
toms were problematic [11], pre-biopsy information must
reflect this if it is effectively to help men manage known
symptoms of biopsy, reduce anxiety and avoid unneces-
sary consultations. Based on these figures and the findings
from this interview study, we propose the inclusion of
additional pre-biopsy information that more accurately re-
flects the prevalence and severity of symptoms and that
should more effectively prepare men.
This study addressed questions raised by previously pub-
lished work from the ProBE study: what caused around
one quarter of men to experience TRUS-Bx symptoms as
problematic [11]; and why those who experienced symp-
toms as problematic also experienced raised anxiety [12].
This interview study revealed both the influence of infor-
mation provision in determining how biopsy and its seque-
lae are experienced and the impact of this on healthcare
contact following biopsy. Most of those seeking healthcare
contact did so because of unexpected haemorrhagic symp-
toms and in fact required no active treatment. In contrast,
the small number of men experiencing post-biopsy infec-
tion reported considerable reluctance to seek healthcare
and one man reported an inappropriate response from
healthcare professionals. A recent systematic review of bi-
opsy complications highlighted that although minor bleed-
ing and urinary complications are relatively common, these
usually require no intervention, whereas serious infective
complications though rare, require prompt intervention
[4]. Information provision is essential in enabling men to
discriminate between minor and serious infective compli-
cations. Evidence also suggests that information provision
impacts on well-being and health outcomes [21,22]. Men in
this study suggested that optimum information provision
included face-to-face discussion with a specialist nurse or
clinician before TRUS-Bx. Previous qualitative investiga-
tions of TRUS-Bx have highlighted emotional costs and
anxiety reported by men undergoing biopsy [17,23-26], and
a link between information provision and anxiety has been
proposed [17,24,26]. Men need time before or after TRUS-
Bx to talk through individual fears and misconconceptions
[24,9]: concerns and misconceptions raised by men in the
present study were highly individual and written PILs can-
not anticipate all concerns.
One quarter of this interview study sample reported feel-
ing unprepared in some way, a figure comparable to the
27.1% reporting one or more symptoms as problematic
during the 35 days post-biopsy [11]. Symptoms were
Table 2 Summary of information that men suggested
should be added to patient information leaflets
Topic Additional information suggested
Pain/Soreness
-Intensity Some men report experiencing intense
pain and/or distress during biopsy.
-Duration Pain and soreness may last up to 4–6
weeks after biopsy.
Bleeding
-Site of bleeding There may be considerable blood loss
immediately following biopsy from the
penis, in the semen, urine and from the
back passage.
-Quantity of blood loss The amount of blood in the semen, urine
and back passage may appear enough to
mask the semen/urine/faeces.
-Duration of bleeding Bleeding may last (or occur intermittently)
for 5 weeks after biopsy.
-Stop/start bleeding Bleeding may stop after a fortnight, and
then restart e.g. a week later.
-Appearance of blood Blood may appear red or black in colour, may
appear as clots or solid lumps or as fluid.
Biopsy procedures
−10-12 cores taken Normally between 10 and 12 biopsy samples
will be taken and each sample requires the
needle to be fired into the prostate
-Anaesthetic Men will be given a local anaesthetic, injected
into the prostate. Occasionally, men feel faint
after biopsy and this is why men are asked to
bring someone to drive them home afterwards.
-Staff present Biopsy will be carried out by an urologist,
radiologist or specialist nurse and a nurse will
also be present. Male and female members of
staff may be present.
Fear of cancer spread No evidence has been found that biopsy
can result in cancer spreading more quickly.
Fear of hospital
acquired infection
The risk of hospital acquired infection is:
• Colonisation with MRSA (0.9% - 1 in 110)
• Clostridium difficile bowel infection
(0.01% - 1 in 10,000)
• MRSA bloodstream infection (0.02% - 1 in 5000)
Other comments from men:
Men who felt well-prepared, reported that health professionals had talked
through the procedure with them before biopsy.
Men who had undergone previous invasive medical procedures felt less
concern about biopsy than those who had not.
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understated in the sample PIL provided by one ProBE
study centre (Additional file 1), when compared to symp-
toms reported in the main ProBE study findings [11] and
those reported here and issues that caused misunderstand-
ing (Table 2) were not all covered (Additional file 1). Key
insights into men’s experience of biopsy and its sequelae
have therefore been combined with quantitative findings
from the ProBE study regarding prevalence of symptoms
[11], to propose comprehensive information to better pre-
pare men for TRUS-Bx (Additional file 2). Delayed or
inappropriate responses to infective symptoms could be
avoided by providing men undergoing prostate biopsy with
a card that details the date and location of the procedure,
antibiotic cover used, and outlining symptoms that should
trigger prompt healthcare consultation. Urologists should
also be aware of the potential impact of adverse biopsy expe-
riences on later decisions about re-biopsy or treatment,
particularly as more men consider AS, which includes
scheduled re-biopsy, as a treatment option for localised PCa.
Recent debate in the UK has criticised variation in existing
patient information for TRUS-Bx and called for a systematic
approach to patient information whereby information is
evidence-based, produced in consultation with patients and
whereby the impact of information is measured [22,27,28].
The proposed TRUS-Bx PIL developed in this study is the
first step in this process, combining latest evidence from the
ProtecT and ProBE studies in accordance with recently pub-
lished UK guidelines on PCa [10]. It will need evaluating,
taking into account local patient and professional views and
tested in different languages if used outside the UK.
The main strength of this study was its use of a quali-
tative methodology enabling exploration and mapping of
how and why anxiety arose, and how it prompted un-
necessary contact with health professionals. It also bene-
fitted from being embedded in the wider prospective
quantitative investigation of the side effects of a system-
atically applied prostate biopsy protocol and recruited an
unusually large sample for an in-depth interview investi-
gation. Limitations include that, as some time has passed
since these data were collected, TRUS-Bx techniques
and information will have evolved. However, elements of
the procedure that took men by surprise (number of
biopsy cores, repeat biopsy feeling more invasive) con-
tinue to be relevant and are not always covered in
current biopsy information. For some participants, inter-
views took place several months after biopsy and, for
some, following radical treatments for PCa. However,
data collection in the ongoing ProtecT study [16] has
shown that long time intervals between biopsy and inter-
view have not resulted in change to men’s narratives, with
both negative and positive experiences of biopsy continu-
ing to be recounted in the same terms, many years after
biopsy. Participants in the ProtecT/ProBE study are
mostly Caucasian and it should be taken into account
that different ethnic groups may report different experi-
ences. Data on interviewees’ education status were not
collected, yet education status can influence under-
standing of and responses to information. The study
took place in a research rather than clinical setting and
the proposed patient information will need testing for
its acceptability and effectiveness in routine care and by
participants with a range of education status and from
a range of socioeconomic backgrounds. However, given
that information provision is likely to receive higher
priority in a research than in a non-research setting where
additional consent processes are required, it can be as-
sumed that similar issues around information provision
would be more likely to arise in a non-research setting.
The proposed information is intended for men who have
already undergone initial PSA testing. Previous research
suggests that information provision may influence men’s
decisions whether to present for PSA testing or undergo
biopsy [29] and this information will need adapting for
men deciding whether to initiate PSA testing. Template or
magnetic resonance imaging (MRI) guided biopsy are be-
coming increasing common and will have a different pro-
file of side effects. However, the key findings of this study
(the impact of providing both comprehensive information
and time for discussion prior to biopsy on subsequent
healthcare contact) are equally applicable to novel proce-
dures. Future research is needed to investigate the finding
that repeat biopsies were experienced as more painful and
invasive.
Conclusions
This study illuminated the experiences of men undergoing
TRUS-Bx and highlighted that men experienced anxiety
associated with biopsy particularly if they were inad-
equately prepared for the procedure or its after-effects.
Men’s experiences have been used to propose a revised
TRUS-Bx PIL and reiterate the need for discussion with a
specialist nurse or clinician prior to undergoing TRUS-Bx.
This approach has potential to reduce anxiety, avoid un-
necessary healthcare consultations and facilitate rapid con-
sultation where appropriate.
Additional files
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Additional file 2: Proposed content for patient information leaflet
for men undergoing Transrectal Ultrasound (TRUS) guided prostate
biopsy.
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